v3.25.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Cash flows used in operating activities:      
Net loss $ (11,771) $ (10,228) [1] $ (191,301) [1]
Adjustments for non-cash items:      
Unrealized gain on changes in fair value of biological assets 0 0 (84)
Realized fair value adjustments on inventory sold or impaired 0 984 4,342
Revaluation of financial instruments (249) (7,223) (6,000)
Issuance costs allocated to warrants granted 48 268 0
Disposal of property, plant and equipment 235 0 0
Common shares and prefunded warrants issued as share-based compensation with related party 758 0 0
Discount expenses in respect of convertible debentures 173 0 0
Depreciation of property, plant and equipment 456 644 3,044
Amortization of intangible assets 1,377 1,758 2,343
Depreciation of right of use assets 351 594 1,944
Impairment of goodwill 495 0 107,854
Impairment of property, plant and equipment 0 0 2,277
Impairment of intangible assets 0 0 7,199
Impairment of right of use assets 0 0 1,914
Finance income, net 1,928 3,019 6,532
Deferred tax payments (benefit), net (150) 394 (3,004)
Share-based payments 369 225 3,767
Revaluation of other current receivable 0 0 3,982
Loss from deconsolidation of Oranim 2,734 0 0
Restructuring expenses 0 0 8,757
Revaluation expenses of investment in affiliate 837 0 0
Revaluation expenses (income) of loans receivables (177) 601 0
Changes in employee benefit liabilities, net (96) (139) (63)
Gain from debts restructuring (960) 0 0
Discount expenses in respect of credit 87 0 0
Total adjustments for non-cash items 8,216 1,125 144,804
Changes in non-cash working capital:      
Increase (decrease) in trade receivables, net (6,287) 2,320 6,058
Increase in other current assets 1,902 1,299 3,622
Decrease in biological assets, net of fair value adjustments 0 0 565
Increase in inventory, net of fair value adjustments 6,261 4,771 883
Increase (decrease) in trade payables 7,845 (6,098) 11,284
Increase (decrease) in other current liabilities (7,147) (750) 12,126
Changes in non-cash working capital 2,574 1,542 34,538
Taxes paid (96) (514) (681)
Net cash used in operating activities (1,077) (8,075) (12,640)
Cash flows used in investing activities:      
Purchase of property, plant and equipment (156) (581) (1,562)
Proceeds from sales of property, plant and equipment 96 0 210
Proceeds from loans receivable 0 0 350
Deconsolidation of subsidiary (346) 0 (406)
Investments in affiliate 0 0 (125)
Loan granted 0 (601) 0
Change in restricted cash (64) 0 0
Net cash used in investing activities (470) (1,182) (1,533)
Cash provided by financing activities:      
Proceeds allocated to issuance of share capital, net of issuance costs 944 1,688 3,756
Proceeds allocated to issuance of warrants measured at fair value, net of issuance costs 1,106 6,585 0
Proceeds received from common shares issued upon options exercised 0 0 333
Repayment of lease liabilities (331) (586) (1,656)
Payment of interest on lease liabilities (52) (63) (1,429)
Proceeds from loans received 2,619 5,482 9,636
Repayment of loans (3,834) (4,827) (4,976)
Interest paid (2,080) (1,664) (902)
Proceeds received from discounted checks 5,453 2,802 0
Net cash provided by financing activities 3,825 9,417 4,762
Effect of foreign exchange on cash (3,228) (796) (2,043)
Change in cash (950) (636) (11,454)
Cash at the beginning of year 1,813 2,449 13,903
Cash at the end of year 863 1,813 2,449
Supplemental disclosure of non-cash activities:      
Right of use assets recognized with corresponding lease liabilities 40 309 613
Common shares issued as settlement of purchase consideration through business combination transactions 0 0 3,061
Common shares and prefunded warrants issued as debts settlement with related party 758 0 0
Common shares and warrants issued as debts settlement with related party 0 1,061 0
Issuance of convertible debentures in exchange for loans (principal and interest) received 2,092 0 0
Revaluation of put option liability versus equity $ 724 $ 1,820 $ 0
[1] Loss per share includes the effect of Reverse Share Split (see also Note 18A below).

Source